<DOC>
	<DOCNO>NCT01231321</DOCNO>
	<brief_summary>A total 100 participant diagnose active rheumatoid arthritis enrol 5 site Russia . Adalimumab administer subcutaneous injection every week , dose escalation weekly dose available participant receive concomitant disease-modifying antirheumatic drug ( DMARDs ) achieve American College Rheumatology 20 ( ACR20 ) criteria 12 week treatment . Efficacy safety measurement perform throughout study .</brief_summary>
	<brief_title>A Study Adalimumab When Added Inadequate Standard Anti-rheumatic Therapy Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This open-label , multicenter study design establish safety efficacy adalimumab treatment moderate severely active rheumatoid arthritis . A total 100 subject inadequate preexist standard anti-rheumatic therapy enrol 5 site Russia .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Males females &gt; = 18 year age . 2 . A negative pregnancy test ( human chorionic gonadotropin serum sample ) woman childbearing potential prior start study treatment . 3 . Female subject either childbearing potential , define postmenopausal ( least 1 year since last menses ) surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control throughout study 150 day study completion : Condoms , sponge , foam , jelly , diaphragm intrauterine device . Contraceptives ( oral , parenteral , patch ) three month prior study drug administration . A vasectomized partner . 4 . American College Rheumatology criterion diagnosis rheumatoid arthritis least 6 month . 5 . Subjects must meet following three criterion : Disease Activity Score ( 28 joint ) equal 3.2 ( Baseline ) At least 6 swollen joint 66 assess At least 8 tender joint 68 assess 6 . Subjects must Creactive protein &gt; = 1.5mg/dL erythrocyte sedimentation rate &gt; = 28 mm/1h . 7 . Unsatisfactory response intolerance prior disease modify antirheumatic drug ( must fail least 1 disease modify antirheumatic drug ) . 8 . Able willing administer subcutaneous injection . 9 . Able willing give write informed consent comply requirement study protocol . 10 . Documented negative purified protein derivative test , define &lt; 5 mm induration , willingness ability start tuberculosis prophylaxis first dose study drug purify protein derivative result positive chest Xray suggestive active tuberculosis history active tuberculosis . 1 . Prior treatment alkylating agent cyclophosphamide chlorambucil within least 5 year enrollment . 2 . Prior treatment intravenous immunoglobulin investigational agent `` chemical '' nature within 30 day , 5 half life product , whichever longer . 3 . Prior treatment cyclosporine within last 6 month . 4 . Prior treatment investigational biologic therapy . 5 . Subject chronic arthritis diagnosis age 17 year . 6 . Subject undergone joint surgery within precede two month ( joint assess within study ) . 7 . History allergic reaction significant sensitivity constituent study drug ( adalimumab ) . 8 . Treatment within last 2 month approve biologic therapy ( e.g . infliximab ) prior Baseline . 9 . Prior treatment total lymphoid irradiation . 10 . History cancer lymphoproliferative disease successfully completely treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix . 11 . History current acute inflammatory joint disease origin rheumatoid arthritis , e.g . mixed connective tissue disease , systemic lupus erythematosus etc . 12 . History uncontrolled diabetes , unstable ischemic heart disease , congestive heart failure ( New York Heart Association IIIIV ) , active peptic ulcer disease , recent stroke ( within 3 month ) condition , opinion investigator , would put subject risk participation protocol . 13 . Subject know immune deficiency , history positive human immunodeficiency virus status immunocompromised . 14 . Persistent chronic infection , severe infection require hospitalization treatment intravenous antibiotic within 30 day , oral antibiotic within 14 day prior enrollment . 15 . Female subject pregnant breastfeed consider become pregnant study 150 day last dose study medication . 16 . History clinically significant drug alcohol abuse last year . 17 . Previous diagnosis sign central nervous system demyelinate disease . 18 . History untreated active tuberculosis , histoplasmosis listeriosis . 19 . History clinically significant hematologic ( e.g . severe anemia , leucopenia , thrombocytopenia ) , renal liver disease ( e.g . fibrosis , cirrhosis , hepatitis ) . 20 . Screening clinical laboratory analysis show follow abnormal laboratory result : Aspartate transaminase alanine transaminase &gt; 1.75 x upper limit normal . Serum total bilirubin &gt; = 1.5 mg/dL ( &gt; = 26 micromol/L ) . Creatinine &gt; 1.5 mg/dL ( 133 micromol/L ) subject &lt; 65 year old &gt; upper limit normal range subject &gt; = 65 year old . Positive Hepatitis B C serology indicative previous current infection . 21 . Subject consider Investigator , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Adalimumab add inadequate standard anti-rheumatic therapy patient active Rheumatoid Arthritis</keyword>
</DOC>